PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- Pfizer Launches ALK Inhibitor Xalkori, Administered to 51 Patients Prior to NHI Price Listing
May 30, 2012
- Kyorin Holdings to Boost Manufacturing System with Transfer of MSD Plant
May 30, 2012
- Shionogi Launches Oxycodone Injections in Response to Request for Development
May 30, 2012
- Takeda Launches ARB Azilva; Will Target Patients Inadequately Controlled with Existing Medications
May 30, 2012
- Cardiovascular Agent Market Increases 2.6% to 1.363 Billion Yen in 2011: Fuji-Keizai
May 30, 2012
- Takeda to Acquire Multilab of Brazil to Boost Business Infrastructure through OTC Drugs
May 29, 2012
- CMIC Subsidiary to Expand Non-Clinical Operations by Business Transfer
May 29, 2012
- Chugai Files NDA for Breast Cancer Treatment Pertuzumab in Japan
May 29, 2012
- Sanofi-aventis Applies for Switch OTC Allegra, PAFSC Committee to Review on June 7
May 28, 2012
- 26 TSE 1st-Section Drug Makers Post Overall Decline in Sales, Profits for FY2011: JPMA
May 28, 2012
- Meiji Seika Pharma Aims to Increase No. of MRs to 900 as Soon as Possible
May 28, 2012
- Nearly 30% Use “Only Neostigmine”: Neuromuscular Antagonists Usage Survey
May 28, 2012
- US Subsidiary of DSP Settles COPD Drug Patent Infringement Suit
May 28, 2012
- DPP-4 Inhibitors Gain Traction, Boosting Diabetes Market by 15.5%: IMS Japan
May 25, 2012
- Zeria Projects 19% Increase in Asacol Sales to 12.2 Billion Yen in FY2012
May 25, 2012
- Japanese Ethical Drug Market Expands by 5.5% to 9.5348 Trillion Yen: IMS Japan
May 25, 2012
- Takeda Files MAA for Alogliptin in Europe
May 25, 2012
- National Cancer Center, Daiichi Sankyo Conclude Comprehensive Joint Research Agreement for Cancer Drug Discovery
May 24, 2012
- RIKEN and Takeda Open Collaboration Center for Developing Drug Discovery Technology for CNS Diseases
May 24, 2012
- Daiichi Sankyo Completes Patient Recruitment in Overseas PIII Trial of ARQ 197 for NSCLC
May 24, 2012
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…